Norwalk virus, also known as Norovirus, is a common intestinal virus that can cause acute gastroenteritis. In recent years, Norwalk virus has become one of the main pathogens causing human gastrointestinal diseases, especially in cold seasons and enclosed environments where the virus can easily spread.
Globally, millions of people are infected with Norwalk virus-induced gastroenteritis every year, with children and the elderly being particularly susceptible to infection. Therefore, the prevention and control of Norwalk virus infection has always been an important part of public health work.
In the following article, we will delve into the basic characteristics, replication process, transmission routes, and the current status of drug and vaccine development for Norwalk virus. This aims to provide a comprehensive understanding and effective response to this health threat.
2. The Infectivity and Pathogenesis of Norovirus
3. Transmission Routes of Norwalk Virus
4. Progress in the Research of Norovirus Vaccine
5. CUSABIO offers various products that are useful for Norwalk virus research
Norwalk virus is a small, non-enveloped, single-stranded RNA virus belonging to the Caliciviridae family and is a common intestinal virus. It is a spherical virus with a diameter of approximately 27-38 nanometers, and has protruding structures on its surface. These protruding structures play an important role in the structure and function of the virus, helping the virus to bind and enter host cells.
The outer shell structure of Norwalk virus is composed of 90 VP1 molecules and 60 VP2 molecules, forming 60 icosahedral (T=3) structures [1]. Both VP1 and VP2 proteins have important immunogenicity, and can induce the human immune system to produce antibodies, thus playing a protective role.
In addition, there are other non-structural proteins in Norwalk virus, such as VPg and NS1-2, which play important roles in the virus replication and infection process [2]. The most important of these are the RNA-dependent RNA polymerase (RdRp) and the protease 3C (3Cpro). RdRp is the core enzyme in the replication process of Norwalk virus, and can replicate RNA templates into new RNA molecules. 3Cpro is an important protease in the replication process of Norwalk virus, which can cleave and process a large number of protein precursors to produce mature virus proteins.
Norovirus mainly infects humans, especially children and the elderly. It enters the body through the mouth, usually spread through food or water, and can also be transmitted through contact with the hands of infected individuals. Due to its high infectivity and widespread distribution, norovirus is one of the main pathogens causing acute gastroenteritis globally.
The pathogenesis of norovirus mainly involves infection of intestinal epithelial cells, disrupting the structure and function of the intestines, and leading to symptoms of diarrhea and gastroenteritis, involving the following aspects:
In summary, norovirus is highly infectious, and its pathogenesis involves multiple factors, including infection, virus replication, immune response, neural regulation, and intestinal microbiota, which together lead to the occurrence of symptoms such as diarrhea and gastroenteritis.
The transmission routes of Norwalk virus are diverse, primarily involving droplet transmission and food and waterborne transmission. These pathways establish multiple connections between the source of infection and the host, providing opportunities for the widespread transmission of the virus within populations.
These transmission pathways facilitate the rapid spread of Norwalk virus within populations, especially in densely populated or shared living spaces where the risk of infection is more pronounced.
As the research on Norwalk virus continues to deepen, scientists are searching for effective vaccines and treatments to prevent and treat Norwalk virus infections [3]. Currently, the vaccines under investigation include oral vaccines and genetic engineering vaccines.
In summary, the development of Norwalk virus vaccine is still in its early stages, and further research and experimentation are needed to determine its safety and effectiveness.
CUSABIO offers Norwalk virus capsid protein-related products that can assist researchers in gaining deeper insights into the structure, infection mechanisms, and immunological characteristics of the Norwalk virus. This can provide more effective means for the prevention and treatment of the disease.
Product Name | Code | Source | Tag Info |
---|---|---|---|
Recombinant Norwalk virus Capsid protein VP1(ORF2) | CSB-YP767779NBAY | Yeast | N-terminal 6xHis-tagged |
Recombinant Norwalk virus Capsid protein VP1(ORF2) | CSB-MP767779NBAY | Mammalian cell | C-terminal Flag-Myc-tagged |
References
[1] Prasad, B. V.,et al. (1999). X-ray crystallographic structure of the Norwalk virus capsid. Science, 286(5438), 287-290.
[2] Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. Journal of virology, 77(22), 12562-12571.
[3] Atmar, R. L.,et al. (2011). Norovirus vaccine against experimental human Norwalk virus illness. New England Journal of Medicine, 365(23), 2178-2187.
[4] Chen, X.,et al. (2012). Norovirus P particle, a novel platform for vaccine development and antibody production. Journal of virology, 86(6), 3219-3227.
[5] Lindesmith, L. C.,et al. (2015). Broad blockade antibody responses in human volunteers after immunization with a multivalent Norovirus VLP candidate vaccine.
Comments
Leave a Comment